| RESEARCH PAPER |
|
| Year : 1991 | Volume
: 23
| Issue : 2 | Page : 75-80 |
Desferrioxamine treatment in aluminium overload patients : An aluminium binding study
AA Moshtaghie, AW Skillen
Correspondence Address:
A A Moshtaghie
 Source of Support: None, Conflict of Interest: None  | Check |
1. The binding of aluminium to serum proteins was investigated using immuno-affinity chromatography technique. Anti-transferrin coupled to CNBr-activated sepharose-4B was used.
2. 82% of the aluminium in the blood circulation was found to be transferrin bound and the remaining was ultrafiltrable.
3. Infusion of desferrioxamine leads to the elevation of plasma aluminium concentration approximately by 225 per cent.
4. It might be concluded that transferrin is the major aluminium carrier protein in the plasma and desferrioxamine may be used in the therapy of aluminium toxicity in aluminium overload patients with chronic renal failure maintained on regular hemodialysis.
[PDF]*
|
